Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268.HK) with a target price of HKD 50, indicating a potential upside of 25% from the current price of HKD 40 [1][5][10]. Core Insights - WuXi AppTec's 2024 performance slightly exceeded previous positive earnings forecasts, with revenue reaching RMB 4.052 billion, representing a year-on-year growth of 90.8%, surpassing the earlier guidance of 85% [5][7]. - The adjusted net profit for 2024 was RMB 1.07 billion, reflecting a significant year-on-year increase of 277.2%, also exceeding prior expectations of 170% growth [5][7]. - The company expects to maintain a revenue growth rate of over 35% for 2025, supported by a strong order backlog of USD 990 million, which is up 71.2% year-on-year [5][7]. - North America is identified as a key growth driver, with its revenue contribution increasing to 50% in 2024, up from 40% in 2023 [5][7]. Financial Performance and Forecast - Revenue and profit forecasts for WuXi AppTec are as follows: - 2023: Revenue of RMB 2.124 billion, net profit of RMB 284 million - 2024: Revenue of RMB 4.052 billion, net profit of RMB 1.07 billion - 2025E: Revenue of RMB 5.569 billion, net profit of RMB 1.302 billion - 2026E: Revenue of RMB 7.618 billion, net profit of RMB 1.739 billion - 2027E: Revenue of RMB 9.987 billion, net profit of RMB 2.356 billion [7][8][9]. - The report projects a compound annual growth rate (CAGR) for revenue exceeding 40% over the next three years under optimistic scenarios [19]. Valuation Metrics - The report adjusts the 2025/2026 estimated net profit upwards by 28% and 24% respectively, primarily due to increased revenue forecasts [5][7]. - The target valuation multiple is set at 1.05x PEG, corresponding to a 31x PE for 2026E, leading to the target price of HKD 50 [5][7].
药明合联（02268）：24年业绩略超预期，维持25年35%收入增速指引